What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to formally report that Vertex Pharmaceuticals has issued a press release containing its consolidated financial results for the year and quarter ended December 31, 2011.

Where can I find the actual financial results for the period?

The actual financial results are not detailed within the 8-K form itself. They are provided in a press release dated February 2, 2012, which is attached as Exhibit 99.1 to this filing and incorporated by reference.

What financial period does this report cover?

This report and the accompanying press release cover the consolidated financial results for the year and the quarter that ended on December 31, 2011.

Does the information in Exhibit 99.1 have specific legal implications under SEC rules?

According to the filing, the information in Exhibit 99.1 (the press release) is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section, unless expressly incorporated by reference into other SEC filings.

VRTX 8-K: Earnings & Results

Summary

Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on February 2, 2012, to report its consolidated financial results for the year and quarter ended December 31, 2011. The filing itself does not contain the detailed financial results but rather incorporates by reference a press release issued on the same date. Investors interested in the specific financial performance, revenue figures, and profit margins for the period should refer to the attached press release (Exhibit 99.1) for a comprehensive overview of the company's operational and financial condition.

Key Highlights

1Vertex Pharmaceuticals filed an 8-K on February 2, 2012.
2The filing announces the release of financial results for the year and quarter ended December 31, 2011.
3The detailed financial results are provided in an attached press release, incorporated by reference as Exhibit 99.1.
4This 8-K serves as formal notification of the company's financial reporting for the period.
5Investors need to consult Exhibit 99.1 for specific financial data and operational performance details.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 2, 2012)

Summary

Key Highlights

Frequently Asked Questions